Literature DB >> 20161509

Lipoprotein Particle Profiles by Nuclear Magnetic Resonance Spectroscopy in Medically-Underserved HIV-Infected Persons.

Barbara Swanson1, Beverly E Sha, Joyce K Keithley, Louis Fogg, Judith Nerad, Richard Novak, Oluwatoyin Adeyemi.   

Abstract

BACKGROUND: HIV infection is associated with dyslipidemia and increased risk for cardiovascular events. Few studies have described lipid status in medically-underserved, HIV-infected ethnic minorities, a group that is characterized by health disparities.
OBJECTIVE: The objective was to characterize the lipid profile of a medically-underserved, largely ethnic minority sample of HIV-infected persons using standard lipid panels and nuclear magnetic resonance (NMR) -derived lipoprotein particle profiles.
METHODS: Participants were recruited from a randomized controlled trial of a dietary supplement to manage HIV-related dyslipidemia (N=132). At the initial screening visit, sociodemographic, clinical, and behavioral data were collected, and fasting peripheral venous blood specimens were obtained and lipid status was analyzed using the standard lipid panel and the NMR-derived lipoprotein particle profile.
RESULTS: Using NMR-derived LDL particle cutoffs, a higher percentage of participants was outside the target range (50%) than when standard LDL cholesterol NCEP cutoffs were used (24%). Antiretroviral therapy, especially protease inhibitor-containing regimens, was associated with higher LDL particle concentration.
CONCLUSION: Substantial numbers of medically-underserved, asymptomatic HIV-infected minorities may be at increased risk for CHD based on NMR-derived lipoprotein values.

Entities:  

Year:  2009        PMID: 20161509      PMCID: PMC2797322          DOI: 10.1016/j.jacl.2009.10.005

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  24 in total

Review 1.  Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy.

Authors:  Elias J Jeyarajah; William C Cromwell; James D Otvos
Journal:  Clin Lab Med       Date:  2006-12       Impact factor: 1.935

2.  The role of immunity and inflammation in the progression of atherosclerosis in patients with HIV infection.

Authors:  Blai Coll; Sandra Parra; Carlos Alonso-Villaverde; Gerard Aragonés; Manuel Montero; Jordi Camps; Jorge Joven; Lluis Masana
Journal:  Stroke       Date:  2007-08-02       Impact factor: 7.914

Review 3.  Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation.

Authors:  John D Brunzell; Michael Davidson; Curt D Furberg; Ronald B Goldberg; Barbara V Howard; James H Stein; Joseph L Witztum
Journal:  Diabetes Care       Date:  2008-04       Impact factor: 19.112

4.  Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction.

Authors:  J H Stein; M A Klein; J L Bellehumeur; P E McBride; D A Wiebe; J D Otvos; J M Sosman
Journal:  Circulation       Date:  2001-07-17       Impact factor: 29.690

5.  Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial.

Authors:  Robert S Rosenson; James D Otvos; David S Freedman
Journal:  Am J Cardiol       Date:  2002-07-15       Impact factor: 2.778

6.  Incidence of myocardial infarction in randomized clinical trials of protease inhibitor-based antiretroviral therapy: an analysis of four different protease inhibitors.

Authors:  Paul M Coplan; Alexander Nikas; Anthony Japour; Karen Cormier; Hilal Maradit-Kremers; Ron Lewis; Yi Xu; Mark J DiNubile
Journal:  AIDS Res Hum Retroviruses       Date:  2003-06       Impact factor: 2.205

7.  Class of antiretroviral drugs and the risk of myocardial infarction.

Authors:  Nina Friis-Møller; Peter Reiss; Caroline A Sabin; Rainer Weber; Antonella d'Arminio Monforte; Wafaa El-Sadr; Rodolphe Thiébaut; Stephane De Wit; Ole Kirk; Eric Fontas; Matthew G Law; Andrew Phillips; Jens D Lundgren
Journal:  N Engl J Med       Date:  2007-04-26       Impact factor: 91.245

8.  LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study - Implications for LDL Management.

Authors:  William C Cromwell; James D Otvos; Michelle J Keyes; Michael J Pencina; Lisa Sullivan; Ramachandran S Vasan; Peter W F Wilson; Ralph B D'Agostino
Journal:  J Clin Lipidol       Date:  2007-12       Impact factor: 4.766

9.  Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1-infected men in the Multicenter AIDS Cohort Study.

Authors:  Sharon A Riddler; Xiuhong Li; James Otvos; Wendy Post; Frank Palella; Lawrence Kingsley; Barbara Visscher; Lisa P Jacobson; A R Sharrett
Journal:  J Acquir Immune Defic Syndr       Date:  2008-07-01       Impact factor: 3.731

10.  Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study.

Authors:  Lewis Kuller; Alice Arnold; Russell Tracy; James Otvos; Greg Burke; Bruce Psaty; David Siscovick; David S Freedman; Richard Kronmal
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-07-01       Impact factor: 8.311

View more
  2 in total

1.  A combined chemometric and quantitative NMR analysis of HIV/AIDS serum discloses metabolic alterations associated with disease status.

Authors:  Tracy R McKnight; Hikari A I Yoshihara; Lungile J Sitole; Jeffery N Martin; Francois Steffens; Debra Meyer
Journal:  Mol Biosyst       Date:  2014-11

2.  Acupuncture to Reduce HIV-Associated Inflammation.

Authors:  Barbara Swanson; Joyce K Keithley; Angela Johnson; Louis Fogg; Oluwatoyin Adeyemi; Beverly E Sha; Kimberly A Snell
Journal:  Evid Based Complement Alternat Med       Date:  2015-04-02       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.